Takara Bio Inc. (JP:4974)
:4974
Want to see JP:4974 full AI Analyst Report?
Top Page
Takara Bio Inc.
(4974)
Select Model
Select Model
Rating:54Neutral
Price Target:
¥1,166.00
▲(48.35% Upside)
Action:Reiterated
Date:05/15/26
The score is held back primarily by weakened financial performance—large 2026 losses and recurring negative free cash flow—despite a strong balance sheet. Technicals are moderately positive and support the score, while valuation remains constrained by negative earnings with only modest dividend support.
Positive Factors
Diversified recurring revenue mix
The company sells consumables, instruments and contract bioprocess services, giving recurring consumables pull-through plus project-based CDMO revenue. This diversification helps stabilize cash cycles and creates multiple durable revenue engines over the medium term.
Negative Factors
Sharp 2026 earnings deterioration
The swing to large operating and net losses in 2026 erodes retained earnings and restricts internal funding for R&D and capacity. Persistent losses would force hard choices—cost cutting, asset sales, or external capital—that could impair long-term competitiveness.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified recurring revenue mix
The company sells consumables, instruments and contract bioprocess services, giving recurring consumables pull-through plus project-based CDMO revenue. This diversification helps stabilize cash cycles and creates multiple durable revenue engines over the medium term.
Read all positive factors
Takara Bio Inc. (4974) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥137.76B
Dividend Yield2.18%
Average Volume (3M)357.12K
Price to Earnings (P/E)―
Beta (1Y)0.63
Revenue Growth-10.48%
EPS Growth-1022.09%
CountryJP
Employees1,838
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-79.71
Shares Outstanding120,415,600
10 Day Avg. Volume362,320
30 Day Avg. Volume357,120
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.33
Price to Sales (P/S)3.43
P/FCF Ratio-15.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)9
Revenue Forecast (FY)¥43.61B
Takara Bio Inc. Business Overview & Revenue Model
Company Description
Takara Bio Inc. is a global biotechnology enterprise, operating through its subsidiaries across Japan, the United States, China, other parts of Asia, Europe, and other international markets. Its operations are divided into two core segments: Bioin...
How the Company Makes Money
Takara Bio makes money primarily by selling life science research products and by providing bioprocess/biopharma services. (1) Research products: The company generates revenue from the sale of reagents, kits, enzymes, and related consumables used ...
Takara Bio Inc. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
70
Positive
Cash Flow
28
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 40.32B | 45.04B | 43.51B | 78.14B | 67.70B |
| Gross Profit | 20.26B | 26.07B | 26.91B | 44.77B | 49.21B |
| EBITDA | 633.00M | 6.50B | 7.90B | 25.98B | 31.70B |
| Net Income | -9.60B | 1.04B | 1.48B | 16.01B | 19.85B |
Balance Sheet | |||||
| Total Assets | 133.66B | 127.61B | 123.21B | 129.20B | 115.71B |
| Cash, Cash Equivalents and Short-Term Investments | 20.45B | 29.55B | 35.42B | 51.85B | 23.63B |
| Total Debt | 10.98B | 1.10B | 968.00M | 972.00M | 1.05B |
| Total Liabilities | 29.69B | 11.76B | 11.42B | 16.75B | 19.65B |
| Stockholders Equity | 103.67B | 115.50B | 111.50B | 112.22B | 95.87B |
Cash Flow | |||||
| Free Cash Flow | -8.99B | -4.03B | -11.07B | 31.15B | -5.55B |
| Operating Cash Flow | 3.58B | 5.84B | 1.71B | 36.90B | 6.99B |
| Investing Cash Flow | -18.68B | -10.91B | -13.04B | -6.69B | -7.07B |
| Financing Cash Flow | 6.12B | -2.26B | -5.23B | -4.12B | -2.07B |
Takara Bio Inc. Technical Analysis
Positive
786.00
Price Trends
1142.76
Positive
1072.14
Positive
977.75
Positive
Market Momentum
0.98
Positive
64.76
Neutral
61.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4974, the sentiment is Positive. The current price of 786 is below the 20-day moving average (MA) of 1143.00, below the 50-day MA of 1142.76, and below the 200-day MA of 977.75, indicating a bullish trend. The MACD of 0.98 indicates Positive momentum. The RSI at 64.76 is Neutral, neither overbought nor oversold. The STOCH value of 61.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4974.
Takara Bio Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | ¥137.76B | -14.35 | ― | 2.18% | -10.48% | -1022.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥23.72B | -32.94 | ― | ― | -11.11% | -187.80% | |
45 Neutral | ¥17.93B | -9.56 | ― | ― | ― | 6.10% | |
43 Neutral | ¥35.24B | -10.32 | ― | ― | -87.41% | 43.60% | |
42 Neutral | ¥12.08B | -20.50 | ― | ― | -25.02% | -697.06% | |
42 Neutral | ¥8.34B | -8.15 | ― | ― | -62.06% | 7.56% |
* Healthcare Sector Average
JP:4974
Takara Bio Inc.
1,144.00
358.00
45.55%
JP:4593
Healios KK
255.00
-286.00
-52.87%
JP:4599
StemRIM Inc.
285.00
-70.00
-19.72%
JP:4978
ReproCELL Inc.
128.00
-64.00
-33.33%
JP:7774
Japan Tissue Engineering Co., Ltd.
595.00
-16.00
-2.62%
JP:7776
CellSeed Inc.
213.00
-302.00
-58.64%
Takara Bio Inc. Corporate Events
Takara Bio Launches Structural Reforms After Deep Operating Loss
May 13, 2026
Takara Bio Inc. has announced structural reforms after posting a consolidated operating loss of ¥4.688 billion for the year ended March 31, 2026, missing its medium-term profit targets amid a global slowdown in life science research and weake...
Takara Bio Swings to Loss, Halts Dividends as It Prepares for Delisting
May 13, 2026
Takara Bio reported a sharp downturn for the fiscal year ended March 31, 2026, with net sales falling 10.5% to ¥40.3 billion and a swing to an operating loss of ¥4.7 billion from a profit a year earlier. Profit attributable to owners of ...
Takara Bio Corrects Share Count Figure in Extraordinary Meeting Notice
May 8, 2026
Takara Bio Inc. has issued a correction to its previously distributed notice convening an extraordinary general meeting of shareholders on proposed share consolidation and related amendments to its Articles of Incorporation. The company clarified ...
Takara Bio Sets May Shareholder Vote as Parent Tightens Grip Ahead of TSE Delisting
Apr 27, 2026
Takara Bio Inc. will convene an extraordinary general meeting of shareholders on May 20, 2026, in Shiga Prefecture to vote on a share consolidation, abolition of the share unit provision, and partial amendments to its Articles of Incorporation. Th...
Takara Bio to Cancel Treasury Shares Ahead of Share Consolidation
Apr 27, 2026
Takara Bio Inc. has resolved at its board meeting to cancel all of its treasury stock, consisting of 300 common shares out of a total 120,415,600 issued shares, under Japan’s Companies Act. The cancellation is scheduled for June 15, 2026, an...
Takara Holdings Tender Offer to Take Takara Bio Private Leads to Delisting
Apr 7, 2026
Takara Bio Inc. announced that its parent company, Takara Holdings Inc., has completed a tender offer for its common shares conducted from February 16 to April 6, 2026. As a result of the successful offer, Takara Bio’s shares will be deliste...
Takara Bio Sets Record Date for Extraordinary Meeting Tied to Parent’s Tender Offer
Mar 26, 2026
Takara Bio Inc. has moved to set April 14, 2026, as the record date for shareholders eligible to vote at an extraordinary general meeting planned for late May. The notice will be published electronically on the company’s website on March 30,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.